Are you a healthcare professional?

This ICLUSIG® (ponatinib) website is for healthcare professionals in the US.

You are now leaving the
ICLUSIG® (ponatinib)
website for
healthcare professionals

This link will take you to a third-party website. Takeda does not control the content contained on third-party websites.

You are now leaving the ICLUSIG® (ponatinib) website for healthcare professionals

This link will take you to another Takeda website.

New Indication Approved

Rewrite your algorithm.

ICLUSIG® (ponatinib) is now indicated for adult patients with chronic phase-CML who are resistant or intolerant to at least 2 prior tyrosine kinase inhibitors.1

 

Reference: 1. ICLUSIG (ponatinib) [prescribing information]. Cambridge, MA: ARIAD Pharmaceuticals, Inc.; 12/2020.